Global Molecular Genetic Testing for Autoimmune Diseases Market Research Report – Segmentation by Disease Type (Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), Type 1 Diabetes, Multiple Sclerosis (MS), Inflammatory Bowel Disease (IBD), and Others); By Technology (Polymerase Chain Reaction (PCR), Microarray, Next-Generation Sequencing (NGS), In Situ Hybridization, and Others); By End-Users (Hospitals and Clinics, Diagnostic Centers, Pharmaceutical and Biotechnology Companies, Research Institutes, and Others); Region – Size, Share, Growth Analysis | Forecast (2024 – 2030)
Published: 2024 - January
Report Code: IM-16112
Format:
Region: Global
Chapter 1. GLOBAL MOLECULAR GENETIC TESTING FOR AUTOIMMUNE DISEASES MARKET – Scope & Methodology
1.1. Market Segmentation
1.2. Scope, Assumptions & Limitations
1.3. Research Methodology
1.4. Primary Sources
1.5. Secondary Sources
Chapter 2. GLOBAL MOLECULAR GENETIC TESTING FOR AUTOIMMUNE DISEASES MARKET – Executive Summary
2.1. Market Size & Forecast – (2023 – 2030) ($M/$Bn)
2.2. Key Trends & Insights
2.2.1. Demand Side
2.2.2. Supply Side
2.4. Attractive Investment Propositions
2.5. COVID-19 Impact Analysis
Chapter 3. GLOBAL MOLECULAR GENETIC TESTING FOR AUTOIMMUNE DISEASES MARKET – Competition Scenario
3.1. Market Share Analysis & Company Benchmarking
3.2. Competitive Strategy & Development Scenario
3.3. Competitive Pricing Analysis
3.4. Supplier-Distributor Analysis
Chapter 4. GLOBAL MOLECULAR GENETIC TESTING FOR AUTOIMMUNE DISEASES MARKET - Entry Scenario
4.1. Regulatory Scenario
4.2. Case Studies – Key Start-ups
4.3. Customer Analysis
4.5. PESTLE Analysis
4.4. Porters Five Force Model
4.4.1. Bargaining Power of Suppliers
4.4.2. Bargaining Powers of Customers
4.4.3. Threat of New Entrants
4.4.4. Rivalry among Existing Players
4.4.5. Threat of Substitutes
Chapter 5. GLOBAL MOLECULAR GENETIC TESTING FOR AUTOIMMUNE DISEASES MARKET - Landscape
5.1. Value Chain Analysis – Key Stakeholders Impact Analysis
5.2. Market Drivers
5.3. Market Restraints/Challenges
5.4. Market Opportunities
Chapter 6. GLOBAL MOLECULAR GENETIC TESTING FOR AUTOIMMUNE DISEASES MARKET – By Disease Type
6.1. Rheumatoid Arthritis (RA)
6.2. Systemic Lupus Erythematosus (SLE)
6.3. Type 1 Diabetes
6.4. Multiple Sclerosis (MS)
6.5. Inflammatory Bowel Disease (IBD)
6.6. Others
Chapter 7. GLOBAL MOLECULAR GENETIC TESTING FOR AUTOIMMUNE DISEASES MARKET – By Technology
7.1. Polymerase Chain Reaction (PCR)
7.2. Microarray
7.3. Next-Generation Sequencing (NGS)
7.4. In Situ Hybridization
7.5. Others
Chapter 8. GLOBAL MOLECULAR GENETIC TESTING FOR AUTOIMMUNE DISEASES MARKET – By End User
8.1. Hospitals and Clinics
8.2. Diagnostic Centers
8.3. Pharmaceutical and Biotechnology Companies
8.4. Research Institutes
8.5. Others
Chapter 9. GLOBAL MOLECULAR GENETIC TESTING FOR AUTOIMMUNE DISEASES MARKET, By Geography – Market Size, Forecast, Trends & Insights
9.1. North America
9.1.1. By Country
9.1.1.1. U.S.A.
9.1.1.2. Canada
9.1.1.3. Mexico
9.1.2. By Disease Type
9.1.3. By Technology
9.1.4. By End User
9.1.5. Countries & Segments - Market Attractiveness Analysis
9.2. Europe
9.2.1. By Country
9.2.1.1. U.K.
9.2.1.2. Germany
9.2.1.3. France
9.2.1.4. Italy
9.2.1.5. Spain
9.2.1.6. Rest of Europe
9.2.2. By Disease Type
9.2.3. By Technology
9.2.4. By End User
9.2.5. Countries & Segments - Market Attractiveness Analysis
9.3. Asia Pacific
9.3.2. By Country
9.3.2.2. China
9.3.2.2. Japan
9.3.2.3. South Korea
9.3.2.4. India
9.3.2.5. Australia & New Zealand
9.3.2.6. Rest of Asia-Pacific
9.3.2. By Disease Type
9.3.3. By Technology
9.3.4. By End User
9.3.5. Countries & Segments - Market Attractiveness Analysis
9.4. South America
9.4.3. By Country
9.4.3.3. Brazil
9.4.3.2. Argentina
9.4.3.3. Colombia
9.4.3.4. Chile
9.4.3.5. Rest South America
9.4.2. By Disease Type
9.4.3. By Technology
9.4.4. By End User
9.4.5. Countries & Segments - Market Attractiveness Analysis
9.5. Middle East & Africa
9.5.4. By Country
9.5.4.4. United Arab Emirates (UAE)
9.5.4.2. Saudi Arabia
9.5.4.3. Qatar
9.5.4.4. Israel
9.5.4.5. South Africa
9.5.4.6. Nigeria
9.5.4.7. Kenya
9.5.4.8. Egypt
9.5.4.9. Rest of MEA
9.5.2. By Disease Type
9.5.3. By Technology
9.5.4. By End User
9.5.5. Countries & Segments - Market Attractiveness Analysis
Chapter 10. GLOBAL MOLECULAR GENETIC TESTING FOR AUTOIMMUNE DISEASES MARKET – Company Profiles – (Overview, Product Portfolio, Financials, Strategies & Developments)
10.1. Abbott Laboratories
10.2. Thermo Fisher Scientific
10.3. Illumina
10.4. Bio-Rad Laboratories
10.5. Roche Diagnostics
10.6. Acacia Research
10.7. Qiagen
10.8. PerkinElmer
10.9. Eurofins Scientific
10.10. Myriad Genetics
Download Sample
Choose License Type
2500
4250
5250
6900
Frequently Asked Questions
The Global Molecular Genetic Testing for Autoimmune Diseases Market was valued at USD 700 million and is projected to reach a market size of USD 984.97 million by the end of 2030. Over the forecast period of 2024–2030, the market is projected to grow at a CAGR of 5%.
An increasing prevalence of diseases and technological advancements are the main factors propelling the Global Molecular Genetic Testing for Autoimmune Diseases Market.
Based on Disease Type, the Global Molecular Genetic Testing for Autoimmune Diseases Market is segmented into Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), Type 1 Diabetes, Multiple Sclerosis (MS), Inflammatory Bowel Disease (IBD), and Others.
North America is the most dominant region for the Global Molecular Genetic Testing for Autoimmune Diseases Market.
Abbott Laboratories, Thermo Fisher Scientific, and Illumina are the key players operating in the Global Molecular Genetic Testing for Autoimmune Diseases Market.
